Silo Pharma Inc. (NASDAQ: SILO), a developmental-stage biopharmaceutical company focused on novel therapeutics and drug delivery systems, announced that its representatives will participate in the IPAC-RS 2026 Nasal Innovation Forum, scheduled for September 16-17, 2026, in Jersey City, New Jersey. This forum is dedicated to advancing nasal drug development, and Silo's involvement signals the company's strategic focus on its lead candidate, SPC-15, which utilizes a novel nose-to-brain delivery approach for the treatment of post-traumatic stress disorder (PTSD).
CEO Eric Weisblum emphasized the importance of the forum, stating that it provides an invaluable opportunity to engage with experts in nasal drug development as the company continues to advance SPC-15. The nose-to-brain route is a cutting-edge strategy that aims to deliver therapeutics directly to the brain, potentially improving efficacy and reducing systemic side effects compared to traditional delivery methods. This approach is particularly relevant for CNS conditions like PTSD, where crossing the blood-brain barrier is a significant challenge.
The announcement comes on the heels of encouraging preclinical data for SPC-15. The formulation and device met predefined specifications for assay, impurities, pH, and microbiological quality over a nine-month period. Additionally, six-month accelerated stability data were consistent and aligned with long-term stability findings. These results are critical for regulatory filings and eventual commercialization, as they demonstrate the product's robustness and reliability.
Silo Pharma is a diversified biopharmaceutical and cryptocurrency treasury company with a therapeutic focus on underserved conditions, including stress-induced psychiatric disorders, chronic pain, and central nervous system diseases. Beyond SPC-15, the company's pipeline includes SP-26 for fibromyalgia and chronic pain, and preclinical assets targeting Alzheimer's disease and multiple sclerosis. Research is conducted in collaboration with leading universities and laboratories, enhancing the credibility and scientific foundation of its programs.
The IPAC-RS Nasal Innovation Forum is a key event for professionals involved in nasal drug product development. By participating, Silo Pharma positions itself at the forefront of this rapidly evolving field, gaining insights that could inform future development strategies. The company's engagement at the forum also provides visibility among industry peers and potential partners, which could be instrumental in advancing its pipeline.
The importance of this participation extends beyond mere presence. It reflects Silo Pharma's proactive approach to regulatory and scientific engagement, which is essential for a company at its stage. The positive stability data for SPC-15 not only de-risks the program but also strengthens the case for continued investment in this innovative therapeutic approach. For investors, this development signals that Silo Pharma is executing on its strategic milestones, potentially enhancing the company's valuation and market position.
As the biopharmaceutical industry increasingly explores alternative delivery methods, Silo Pharma's focus on nose-to-brain delivery could differentiate it in a crowded market. The company's commitment to addressing PTSD, a condition with limited effective treatments, highlights the potential public health impact of its work. With the forum approaching, all eyes will be on Silo Pharma as it showcases its progress and future plans for SPC-15.
